Exagen Inc. Expands In-Network Access with Evolutions Healthcare Systems
March 30 2022 - 8:25AM
Exagen Inc. (Nasdaq: XGN), a leading provider of
autoimmune testing solutions, announced today that AVISE® tests
have entered into an in-network agreement with Evolutions
Healthcare Systems offering access to enhanced care to
participating members. The agreement includes Exagen’s AVISE® Lupus
and AVISE® CTD tests making AVISE diagnostic testing available as
an in-network benefit.
“Exagen continues to expand its presence within the payor
community. The partnership with Evolutions Healthcare Systems will
allow their participating health plans the ability to offer AVISE
testing as an in-network benefit1 to enable a timely and accurate
differential diagnosis to improve outcomes for complex autoimmune
diseases, including SLE,” said Ron Rocca, Exagen’s President and
CEO.
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for
patients suffering from debilitating and chronic autoimmune
diseases by enabling timely differential diagnosis and optimizing
therapeutic intervention. Exagen has developed and is
commercializing a portfolio of innovative testing products under
its AVISE® brand, several of which are based on our proprietary
Cell-Bound Complement Activation Products, or CB-CAPs, technology.
Exagen’s goal is to enable providers to improve care for patients
through the differential diagnosis, prognosis, and monitoring of
complex autoimmune and autoimmune-related diseases, including
rheumatoid arthritis and lupus. For further information please
visit www.exagen.com.
About Evolutions Healthcare Systems, Inc.
Evolutions has been offering customized Provider Network
solutions to Self-insured Employers, Insurance Carriers, and
Third-Party Administrators through our direct network of Hospitals,
Physicians, and Specialists for the past 30 years. In addition to
our network of healthcare professionals, Evolutions provides a
comprehensive suite of Healthcare Management solutions and Claims
Processing services.
Specialties: Custom PPO Network Development for Group Health,
Workers Compensation, Auto, Student Health Plans and International
access. IT specialists in network aggregation and claims flow
management, repricing and claims review.
For further information please visit www.ehsppo.com
1Network benefits and coverage are determined by the
participating health plans.
Forward Looking Statements
Exagen cautions you that statements in this press release
regarding matters that are not historical facts are forward-looking
statements. These statements are based on Exagen's current beliefs
and expectations. Such forward-looking statements include, but are
not limited to, statements regarding the expected benefits of the
positive medical policy coverage for the AVISE CTD test with
Evolutions Healthcare Systems, including the availability and
expected use of the AVISE CTD test through the Evolutions
Healthcare Systems network, and any potential for increased use of
the AVISE CTD laboratory test. The inclusion of forward-looking
statements should not be regarded as a representation by Exagen
that any of its plans will be achieved. Actual results may differ
from those set forth in this press release due to the risks and
uncertainties inherent in Exagen’s business, including, without
limitation: the COVID-19 pandemic may continue to adversely affect
our business, financial condition and results of operations,
including as a result of shutdowns of its facilities and operations
as well as those of its suppliers and courier services, impeding
patient movement and interruptions to healthcare services causing a
decrease in test volumes, disruptions to the supply chain of
material needed for its tests, its sales and commercialization
activities and its ability to receive specimens and perform or
deliver the results from its tests, and delays in ongoing and
planned clinical trials involving its tests; Exagen’s commercial
success depends upon attaining and maintaining significant market
acceptance of its testing products and promoted therapeutics among
rheumatologists, patients, third-party payors and others in the
medical community; Exagen’s ability to successfully execute on its
business strategies; third party payors not providing coverage and
adequate reimbursement for Exagen’s testing products or promoted
therapeutics; Exagen’s ability to obtain and maintain intellectual
property protection for its testing products; regulatory
developments affecting Exagen’s business; and other risks described
in the company’s prior press releases and Exagen’s filings with the
Securities and Exchange Commission (SEC), including under the
heading “Risk Factors” in the company’s Annual Report on Form 10-K
for the year ended December 31, 2021 and any subsequent filings
with the SEC. You are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and Exagen undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date hereof. All forward-looking statements are qualified
in their entirety by this cautionary statement, which is made under
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995.
Investor RelationsExagen Inc. Ryan
Douglasrdouglas@exagen.com 760.560.1525
CompanyExagen Inc.Kamal Adawi, Chief Financial
Officerkadawi@exagen.com 760.477.5514
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Sep 2023 to Sep 2024